Navigation Links
A new measure for the malignancy of melanoma
Date:3/12/2009

Every tumor, starting from a size of a few millimeters, depends on a supply of nutrients and oxygen. Therefore, using special growth factors, it induces vascular wall cells of neighboring blood vessels to sprout new capillaries in order to get connected to the blood circulation.

This process called angiogenesis involves a number of different growth factors and their respective receptors on the vascular wall cells. The departments of Prof. Dr. Hellmut Augustin and Prof. Dirk Schadendorf of DKFZ and Mannheim Medical Faculty of the University of Heidelberg have investigated the role of a growth factor called angiopoietin-2 (Ang2) in malignant melanoma. The docking station of Ang2 is the receptor Tie2 on the surface of endothelial cells, which form the inner lining of blood vessels. Together with other signaling molecules, Ang2 induces sprouting of endothelial cells and the formation of new capillaries.

When measuring the Ang2 concentrations in blood samples of melanoma patients, the investigators discovered that larger tumors and more advanced disease stages correlate with high levels of Ang2. If one tracks the Ang2 levels of individual patients over time, a rise parallel to disease progression can be observed. In contrast, patients who have lived with the disease for a long time, i.e., whose disease is not or only slightly progressive, have lower Ang2 levels. The scientists found out that Ang2 concentration in blood serum is a more precise indicator of the progression and stage of the disease than previously used biomarkers.

This close association between melanoma progression and Ang2 level prompted the question of whether the Ang2 growth factor really only stimulates vascularization in the tumor or whether it has additional influence on the properties of the cancer cells themselves. Such an effect had not yet been proposed for any one of the various growth factors which act on the cells of the vascular walls. Melanoma cells were really found to produce both soluble Ang2 and the matching receptor, Tie2, on their own cell membrane. As a result, they are theoretically capable of activating themselves. In order to check this, researchers switched off the Ang2 production in melanoma cells using a genetic trick. Test systems in the culture dish subsequently revealed that the skin cancer cells had lost their ability to migrate. The migration tendency of cancer cells is regarded as important information about their ability to invade other tissue in the body and metastasize.

The tumor appears to seize the signaling system of vascularization and, thus, to strengthen its malignant properties. "Ang2 is a very promising candidate," Hellmut Augustin comments on the results, both as a biomarker for better monitoring of disease progression and as a target structure for therapy measures." Blocking Ang2 might not only attack the tumor's blood supply, but also reduce its malignant growth.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Neck Fat a Measure of Heart Risk
2. Study tests reliability of more accurate measure of patient pain
3. BurrellesLuce VP Johna Burke to Be Featured Presenter For PRSA's March 9th Free Webinar on 'Smart Measurement'
4. Computer-aided system effectively detects and measures pneumothoraces in chest trauma patients
5. New findings measure precise impact of fat on cancer spread
6. Study Shows Simple Measures May Help Prevent Sudden Death Event in Young Athletes
7. LENA Foundation Technology Measures Effectiveness of Autism Therapy
8. BurrellesLuce VP Johna Burke Among Measurement Experts To Speak at Feb. 25 Meeting of PRSA's National Capital Chapter
9. Should intra-abdominal pressure measurement be a routine for all pancreatitis patients?
10. URAC Calls for Public Comment on Revisions to its Pharmacy Benefit Management (PBM) and Drug Therapy Management (DTM), Version 2.0 Standards and NEW Performance Measures, and PHARM Core, Version 3.0 Standards
11. Efficacy of stents is improved when their placement is determined by arterial blood flow measurement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... will spark a conversation on the current obstacles facing infection prevention and offer ... preventable deaths caused by these infections. , The print component of “Fighting ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Huebner Road. The clinic is the group’s 7th location in San Antonio and 23rd ... PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... 2017 , ... As the standards bearer of advanced cancer ... positions them as the go-to thought leader in all matters concerning oncology nursing. ... always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... 2017 , ... “Vintage and Harvest A Cultivation of Christian Love” is the ... in North Carolina with his wife, Anna Marie. He and his wife are the ... is also the author of “Shadow and Substance.” , “Love, the agape kind, is ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017  Zymo Research Corp., also known ... Inc., who designs, manufactures and distributes liquid ... teams Zymo Research,s DNA methylation detection and ... products with Hamilton,s high-throughput automation platforms. Zymo ... microbiomics and RNA isolation for use on ...
(Date:3/24/2017)... , March 24, 2017   The ... organization within medical affairs in the pharmaceutical industry ... the chair of a newly formed scientific advisory ... members to form the first ever medical affairs ... For more information about the ACMA, please visit  ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
Breaking Medicine Technology: